Clinical trials: Primary Ovarian Insufficiency
Menopause, Vasomotor; Syndrome
Efficacy of Nano-Pso Therapy in Menopause
Vasomotor syndrome is prevalent in 85% of postmenopausal women, hormone therapy in menopause is first-line therapy, but 38% of patients have some contraindication for its use.
- Trial name
- NCT06432816
- Testing
- NANO-PSO
- Where
- Mexico
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Distribuidora Biolife SA de CV
Perimenopausal Disorder, Menopause
Inovium Ovarian Rejuvenation Trials
The Inovium Ovarian Rejuvenation Treatment is a PRP-based autologous treatment used in combination with a stimulated IVF sequence and Pre-Implantation Genetic Screening to treat infertility in women experiencing menopause…
- Conditions
- Perimenopausal Disorder, Menopause, Menopause, Premature, Menopause Related Conditions
- Trial name
- NCT03178695
- Testing
- Autologous PRP injection into human ovarian tissue
- Where
- United States
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Ascendance Biomedical
Premature Ovarian Insufficiency
Phase 1 Clinical Trial of CordSTEM-ST
This clinical study will evaluate the safety and tolerability of CordSTEM-ST after administering a single dose in patients with premature ovarian insufficiency (POI), as well as identify the maximum tolerated dose (MTD) and…
- Trial name
- CBT210-POI_P1 (NCT06578039)
- Testing
- umbilical cord-derived mesenchymal stem cell
- Where
- South Korea
- Volunteers
- 6 people
- Sponsor
- CHABiotech CO., Ltd
Premature Ovarian Insufficiency
Phase Ⅰ/Ⅱa Trial Evaluating Intravenous hUC-MSCs Injection for Safety, Tolerability and Efficacy in Patients With POI
A Phase I/IIa clinical study evaluating the safety, tolerability and efficacy of intravenously administered human umbilical cord mesenchymal stem cell (hUC-MSCs) injection in patients with premature ovarian insufficiency (POI).
- Trial name
- NCT07775391
- Testing
- hUC-MSCs Injection (Phase I), hUC-MSCs Injection (Phase IIa)
- Where
- China
- Volunteers
- 59 people
- Sponsor
- Shenzhen Wingor Biotechnology Co., Ltd.
Diminished Ovarian Reserve (DOR), Primary Ovarian Insufficiency (Poi)
Safety and Efficacy of Autologous Adipose-Derived Regenerative Cells (ADRCs) Injection for Improving Diminished Ovarian Reserve
Diminished Ovarian Reserve (DOR) poses significant challenges to fertility and hormonal health, with limited effective treatments.
- Conditions
- Diminished Ovarian Reserve (DOR), Primary Ovarian Insufficiency (Poi), Ovarian Failure, Premature
- Trial name
- ARISE-01 (NCT07117682)
- Testing
- Autologous Adipose-Derived Regenerative Cells (ADRCs) Intraovarian Injection
- Volunteers
- 25 people
- Sponsor
- Cytori Therapeutics
Premature Ovarian Failure，
Stem Cell Therapy Combined Hormone Replacement Therapy in Patients With Premature Ovarian Failure
Premature ovarian failure (POF) refers the occurrence of amenorrhoea, elevated serum gonadotrophins and hypoestrogenism levels in female before the age of 40.
- Trial name
- NCT01742533
- Testing
- human umbilical cord mesenchymal stem cells, hUCMSCs and hCBMNCs, human cord blood mononuclear cells
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Shenzhen Beike Bio-Technology Co., Ltd.
Primary Ovarian Insufficiency, Vaginitis
A Study To Compare The Amount Of Premarin Components That Is Absorbed Into The Blood Of Japanese Healthy Postmenopausal Women Following Oral Administration Of Two Different Tablets Of Premarin Under Fast and Fed Conditions.
The purpose of this study is to assess the bioequivalence and food effect for a new Premarin formulation compared with a Premarin reference tablet in Japanese healthy postmenopausal women.
- Conditions
- Primary Ovarian Insufficiency, Vaginitis, Metrorrhagia, Menopause
- Trial name
- NCT01436513
- Testing
- Premarin reference tablet (fasted), Premarin new tablet (fasted), Premarin reference tablet (fed)
- Where
- Japan
- Volunteers
- 72 people, healthy volunteers welcome
- Sponsor
- Pfizer
Primary Ovarian Insufficiency (Poi)
Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in the Treatment of Primary Ovarian Insufficiency
The goal of this clinical trial is to evaluate the safety, tolerability and efficacy of human umbilical cord mesenchymal stem cell injection (HS_SW01 cells injection) in patients with Primary Ovarian Insufficiency (POI).
- Trial name
- HS_SW01 (NCT07551895)
- Testing
- HS_SW01 cells injection
- Volunteers
- 21 people
- Sponsor
- Shenzhen Huishan Biotechnology Co., Ltd.
Premature Ovarian Insufficiency, Diminished Ovarian Reserve
A Proof of Concept Study to Evaluate Exosomes From Human Mesenchymal Stem Cells in Women With Premature Ovarian Insufficiency (POI)
The VL-POI-01 study is designed to evaluate the safety and efficacy of human placental mesenchymal stem cell derived exosome treatment in patients with premature ovarian insufficiency (POI) and diminished ovarian reserve.
- Trial name
- VL-POI-01 (NCT06072794)
- Testing
- VL-PX10
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Vitti Labs, LLC
Premature Ovarian Failure
The Safety and Efficiency Study of Mesenchymal Stem Cell (19#iSCLife®-POI) in Premature Ovarian Insufficiency
Evaluate the safety of human umbilical cord mesenchymal stem cells (hucMSCs) in POI treatment; Evaluate the effective hucMSCs in POI treatment.
- Trial name
- NCT03816852
- Testing
- hucMSCs
- Where
- China
- Volunteers
- 12 people
- Sponsor
- Sclnow Biotechnology Co., Ltd.
Amyotrophic Lateral Sclerosis (ALS), Angina, Stable
Quest to Analyze One Thousand Humans Meditating
This study will be focused on assessing the molecular, physiological, and emotional correlates of an intensive meditation experience in the context of a retreat setting in a large 2000 plus-person cohort comprised of healthy and…
- Conditions
- Amyotrophic Lateral Sclerosis (ALS), Angina, Stable, Anxiety, Asthma
- Trial name
- QUANTUM (NCT06583395)
- Testing
- Advanced multi-component meditation practice
- Where
- United States
- Volunteers
- 3,000 people, healthy volunteers welcome
- Sponsor
- Tobias Moeller-Bertram
Primary Ovarian Insufficiency, Poor Ovarian Response
Single Center, Prospective Controlled Pilot Study of the OvaPrime Procedure
This is a single center, prospective, controlled pilot safety research study. The primary objective of this research study is to assess the safety with the use of the OvaPrime procedure in women who are diagnosed with either…
- Trial name
- NCT03021915
- Testing
- OvaPrime Treatment
- Where
- Canada
- Volunteers
- 81 people
- Sponsor
- OvaScience, Inc.
Ovarian Failure, Perimenopausal Disorder
Ovarian Rejuvenation Using Platelet Rich Plasma (PRP) & Autologous Tissue Stromal Vascular Fraction (tSVF) and Cell Enriched tSVF
Trial of imaging guided intra-ovarian injection to improve ovarian function in clinical settings of Premature Ovarian Failure, Perimenopausal and /or early postmenopausal symptomatology and related hormonal deficiencies.
- Conditions
- Ovarian Failure, Perimenopausal Disorder, Hormone Disturbance
- Trial name
- OVAR-REJUV (NCT04444245)
- Testing
- lipoaspiration harvest tSVF, Platelet Rich Plasma, Endovaginal Ultrasound
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Black Tie Medical, Inc.
Premature Ovarian Insufficiency
Treatment of Premature Ovarian Insufficiency Using Bone Marrow Cells
investigator is doing single armed clinical interventional study to treat premature ovarian insufficiency with autologous bone marrow derived mononuclear cells to be given systematically and locally to the ovaries under…
- Trial name
- alfarah (NCT06302543)
- Testing
- autologous bone marrow cells injection
- Where
- Iraq
- Volunteers
- 10 people, healthy volunteers welcome
- Sponsor
- abdulmajeed hammadi
POI
Safety and Efficacy of YB-1113 in Treatment of POI
This phase 1 study is to evaluate the safety and tolerability of YB-1113 administered via intravenous (IV) infusion in the treatment of premature ovarian insufficiency (POI).
- Trial name
- NCT05494723
- Testing
- YB-1113
- Volunteers
- 6 people
- Sponsor
- Bright Cell, Inc.